Although advancing age can greatly increase the complexities of treating metastatic breast cancer, chronological age alone is insufficient to determine the type or intensity of treatment. Older patients require an individualized approach that takes into account the patient's physical ability, social circumstances and mental capacity to tolerate treatment. This section features three older women treated with eribulin for metastatic breast cancer. In the first case, a 70-year-old woman maintained stable disease into her 34th month of treatment with third-line eribulin. In the remaining cases, two heavily pretreated women (80 and 90 years, respectively) with metastatic disease and liver involvement presented objective radiological benefit to later-line eribulin along with prolonged clinical improvement and good tolerability.

Hormonal therapy has been the treatment axis of metastatic prostate cancer since 1940. Identifying rare forms of debut is important in order to initiate the best treatment as soon as possible. Intravascular disseminated coagulopathy (DIC) related to prostate cancer is mostly presented as chronic forms. Acute forms can also be the way of presentation, recognizing them is crucial due to its life threatening nature. Here, we present a case of debut of metastatic prostate cancer as an acute DIC. Reporting this case is important because of the unfrequently presentation and to consider combined chemohormonal therapy since the diagnosis.

Background: Transverse colon cancer (TCC) accounts for 10% of all colon cancers. Unlike right (RCC) and left colon cancer (LCC), TCC shows neither reliable prognostic factors nor specific outcome data yet. Methods:We retrospectively studied patients affected by TCC, defined as originating distally to the hepatic flexure and proximally to the splenic flexure, diagnosed between 2007 and 2018 in 5 Italian centres. Patients' clinicopathological characteristics, treatments, objective response rate (ORR), progression-free survival (PFS) and overall survival (OS) were analysed, with the aim of describing the outcome of multi-institutional stage I-IV TCC.Results: We identified 89 Patients, with a median age of 67 (range 41-90) years, 54 (61%) male, most of them with good performance status. TCC presented as IV, III, II and I stage in 52%, 21%, 24%, and 3% of cases, respectively. Intestinal occlusion was the first symptom in 29% of cases, anaemia in 41%, and pain in 10%. Molecularly, 7(8%) tumours were microsatellite instability-high, 40 (45%) were RAS wild type, and 13 (15%) were BRAF-mutant. Most of them underwent chemotherapy in the adjuvant setting. Thirty-three percent of patients developed metachronous metastases, especially in the liver (54%), peritoneum (30%) and the lung (11%). Treatment options for stage IV patients in first-line setting included 5 fluorouracil-based chemotherapy alone (29%), eventually added to a targeted anti-VEGF (45%) or anti-EGFR (26%) drugs according to the tumor molecular profile. The ORR was 33%, 59%, and 54%, respectively. With a median follow up of 50 months, the median PFS was 7 v 11 v 21 months (HR ¼ 0.76, 95%CI 0.58-1.01) and OS was 16 v 34 v 32 months (HR ¼ 0.85, 95%CI 0.64-1.13) with chemo alone, plus anti-VEGF and anti-EGFR targets, respectively. abstracts Annals of Oncology Volume 31 -Issue S3 -2020 S203